Fampridine-SR Phase III Data Support Filing For Multiple Sclerosis, Acorda Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Company targets first quarter 2009 for NDA submission; will position Fampridine-SR as an add-on to immunomodulators.
You may also be interested in...
Acorda’s Full Fampridine Data Don’t Disappoint
Multiple sclerosis walking test scores unveiled at Montreal meeting.
Acorda’s Full Fampridine Data Don’t Disappoint
Multiple sclerosis walking test scores unveiled at Montreal meeting.
Industry Roundtable: Neurotech Execs Discuss Innovation, Challenges, Next Steps
In Part I of a series, panelists discuss outcomes measures in a sector with unique regulatory conditions and the need for biomarkers.